The Lancet, Early Online Publication, 24 June 2013
Summary
Background
Characterisation
of the severity profile of human infections with influenza viruses of
animal origin is a part of pandemic risk assessment, and an important
part of the assessment of disease epidemiology. Our objective was to
assess the clinical severity of human infections with avian influenza A
H7N9 virus, which emerged in China in early 2013.
Methods
We
obtained information about laboratory-confirmed cases of avian
influenza A H7N9 virus infection reported as of May 28, 2013, from an
integrated database built by the Chinese Center for Disease Control and
Prevention. We estimated the risk of fatality, mechanical ventilation,
and admission to the intensive care unit for patients who required
hospital admission for medical reasons. We also used information about
laboratory-confirmed cases detected through sentinel influenza-like
illness surveillance to estimate the symptomatic case fatality risk.
Findings
Of
123 patients with laboratory-confirmed avian influenza A H7N9 virus
infection who were admitted to hospital, 37 (30%) had died and 69 (56%)
had recovered by May 28, 2013. After we accounted for incomplete data
for 17 patients who were still in hospital, we estimated the fatality
risk for all ages to be 36% (95% CI 26—45) on admission to hospital.
Risks of mechanical ventilation or fatality (69%, 95% CI 60—77) and of
admission to an intensive care unit, mechanical ventilation, or fatality
(83%, 76—90) were high. With assumptions about coverage of the sentinel
surveillance network and health-care-seeking behaviour for patients
with influenza-like illness associated with influenza A H7N9 virus
infection, and pro-rata extrapolation, we estimated that the symptomatic
case fatality risk could be between 160 (63—460) and 2800 (1000—9400)
per 100 000 symptomatic cases.
Interpretation
Human
infections with avian influenza A H7N9 virus seem to be less serious
than has been previously reported. Many mild cases might already have
occurred. Continued vigilance and sustained intensive control efforts
are needed to minimise the risk of human infection.
Funding
Chinese
Ministry of Science and Technology; Research Fund for the Control of
Infectious Disease; Hong Kong University Grants Committee; China—US
Collaborative Program on Emerging and Re-emerging Infectious Diseases;
Harvard Center for Communicable Disease Dynamics; US National Institute
of Allergy and Infectious Disease; and the US National Institutes of
Health.
No comments:
Post a Comment